Targeting Leukemia Cells with Gemtuzumab Ozogamicin
- 1 September 2000
- journal article
- review article
- Published by Wiley in Cancer Practice
- Vol. 8 (5) , 254-256
- https://doi.org/10.1046/j.1523-5394.2000.85010.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublinesLeukemia, 2000
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic SyndromeBlood, 1999
- Selective Ablation of Acute Myeloid Leukemia Using Antibody-Targeted Chemotherapy: A Phase I Study of an Anti-CD33 Calicheamicin ImmunoconjugateBlood, 1999
- Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparisonLeukemia, 1998
- Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosisChemistry & Biology, 1994
- A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group [see comments]Blood, 1994
- Anti-CD33 Monoclonal Antibody M195 for the Therapy of Myeloid LeukemiaLeukemia & Lymphoma, 1993
- Expression of normal myeloid-associated antigens by acute leukemia cellsBlood, 1986